← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,994	+61	+2%	$256B
2	2 Merck MRK $364B	2,497	+20	+0.8%	$147B
3	3 Pfizer PFE $166B	2,443	+6	+0.2%	$129B
4	4 AbbVie ABBV $501B	2,412	+187	+8%	$121B
5	5 Bristol-Myers Squibb BMY $121B	2,191	+43	+2%	$98.8B
6	6 Amgen AMGN $230B	2,091	+63	+3%	$107B
7	7 Gilead Sciences GILD $190B	1,626	-16	-1%	$76.4B
8	8 Novartis NVS $279B	1,129	-3	-0.3%	$20.8B
9	9 Regeneron Pharmaceuticals REGN $80.1B	933	+117	+14%	$57.9B
10	10 GSK GSK $95.9B	841	+24	+3%	$12.5B
11	11 AstraZeneca AZN $251B	670	+66	+11%	$22.7B
12	12 DELISTED Exact Sciences EXAS	513	+38	+8%	$11.5B
13	13 Incyte INCY $22.6B	500	+10	+2%	$21.4B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	493	+101	+26%	$27.3B
15	15 Jazz Pharmaceuticals JAZZ $13.6B	384	-23	-6%	$5.75B
16	16 Exelixis EXEL $15.1B	375	+38	+11%	$6.06B
17	17 Guardant Health GH $21.9B	325	+37	+13%	$6.85B
18	18 Takeda Pharmaceutical TAK $60.7B	309	-4	-1%	$2B
19	19 NeoGenomics NEO $2.17B	285	+13	+5%	$3.17B
20	20 Qiagen QGEN $9.41B	276	+16	+6%	$6.21B
21	21 Halozyme HALO $13.3B	265	+55	+26%	$3.63B
22	22 Iovance Biotherapeutics IOVA $6.44B	257	+38	+17%	$3.88B
23	23 DELISTED Blueprint Medicines BPMC	235	+21	+10%	$4.39B
24	24 BeOne Medicines Ltd ONC $39.8B	220	+5	+2%	$9.45B
25	25 Natera NTRA $56.9B	219	+28	+15%	$3.87B